HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 1. NON-STATIN HYPOLIPIDEMIC MEDICATIONS
Abstract
This article is devoted to discussion about main aspects of current use of non-statin hypolipidemic drugs according last international guidelines (including fibrates, nicotinic acid, resins, polyunsaturated fatty acids, ezetimibe, PCSK9-inhibitors). For each group mechanism of action, effects on lipid profile, main results of randomized trials and practical use approaches are shortly represented.
About the Authors
A. E. Bagriy
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
A. I. Dyadyk
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
M. V. Khomenko
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
I. N. Tsiba
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
V. A. Efremenko
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
E. V. Shchukina
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
O. A. Prikolota
Donetsk national medical university named after M.Gorkiy
Russian Federation
Russian Federation
References
1. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Рекомендации Российского кардиологического общества, Национального общества по изучению атеросклероза и Российского общества кардиосоматической реабилитации и вторичной профилактики (V пересмотр). - М., 2012.
2. Сусеков А. В. Современные подходы в лечении дислипидемий: от научных дискуссий к конкретному больному // Медицинский Совет. 2015. № 12. С. 94-102
3. ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults / N. J. Stone, J. Robinson, A. H. Lichtenstein [et al.] // J. Amer. Coll. Cardiol. 2014. Vol. 63, N 25. P. 2889-2934.
4. Opie L. H., Gersh B. J. Drugs for the heart. - Elsevier, 2013. - 592 p.
5. Antman E. M., Jessup M. Clinical practice guidelines for chronic cardiovascular disorders: a roadmap for the future // J. Amer. Med. Ass. 2014. Vol. 311, N 12. P. 1195-1196.
6. Jukema J. W., Cannon C. P., de Craen A. J. M. et al. The controversies of statin therapy. Weighing the evidence/ // J. Amer. Coll. Cardiol. 2012. Vol. 60. P. 875-881.
7. Stone N. J., Lloyd-Jones D. M. Lowering LDL Cholesterol Is Good, but How and in Whom? // N. Engl. J. Med. 2015. Vol. 372. P. 1564-1565.
8. Campos-Outcalt D. The new cardiovascular disease prevention guidelines: what you need to know // J. Fam. Pract. 2014. Vol. 63, N2. P. 89-93
9. Jacobson T. A., Ito M. K., Maki K. C. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1 // J. Clin. Lipidol. 2014. Vol. 8, N 6. P. 554-561
10. Jacobson T. A., Maki K. C., Orringer C. E. et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 [Электронный ресурс] // J. Clin. Lipidol. 2015. Vol. 9, N 6 Suppl. P. S1 - S122. Режим доступа к журн.: http://www.lipidjournal.com/pb/assets/raw/ Health%20Advance/journals/jacl/NLA_ Recommendations_manuscript. pdf
11. De Caterina R. ω - 3 Fatty Acids in Cardiovascular Disease // N. Engl. J. Med. 2011. Vol. 364. P. 2439-2450.
12. Reiner Z., Catapano A. L., De Baker G. et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. 2011. Vol. 32. P. 1769-1818.
13. Goldfine A. B., Kaul S., Hiatt W. R. Fibrates in the Treatment of Dyslipidemias - Time for a Reassessment // N. Engl. J. Med. 2011. Vol. 365, N 6. P. 481-484.
14. Lloyd-Jones D. M. Niacin and HDL Cholesterol - Time to Face Facts // N. Engl. J. Med. 2014. Vol. 371, N 3. P. 271-273.
15. Lee J. M. S., Robson M. D., Yu Ly-Mee et al. Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function A Randomized, Placebo-Controlled, Magnetic Resonance Imaging Study // J. Amer. Coll. Cardiol. 2009. Vol. 54, N. 19. P. 1787-1794. 16. The HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in HighRisk Patients // N. Engl. J. Med. 2014. Vol. 371. P. 203- 212. 17. Crea F., Niccoli G. Ezetimibe and Plaque Regression Cholesterol Lowering or Pleiotropic Effects? // J. Amer. Coll. Cardiol. 2015. Vol. 66, N 5. P. 508-510.
16. Cannon C. P., Blazing M. A., Giugliano R. P. et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes // N. Engl. J. Med. 2015. Vol. 372. P. 2387- 2397.
17. Tsujita K., Sugiyama S., Sumida H. et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention The Multicenter Randomized Controlled PRECISE-IVUS Trial // J. Amer. Coll. Cardiol. 2015. Vol. 66. P. 495-507.
18. Chew E. Y. Fatty Acids and Retinopathy // N. Engl. J. Med. 2011. Vol. 364. P. 1970-1971.
19. The ORIGIN Trial Investigators. ω - 3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia // N. Engl. J. Med. 2012. Vol. 367. P. 309-318.
20. Клинические исследования моноклональных антител против пропротеиновой конвертазы субтилизин-кексинового типа 9 / Астракова К. С., Рагино Ю. И., Шахтшнейдер Е. В., Воевода М. И. // Атеросклероз. 2015. N 2. C. 43-49.
21. Robinson J. G., Farnier M., Krempf M. et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events // N. Engl. J. Med. 2015. Vol. 372. P. 1489-1499.
22. Sabatine M. S., Giugliano R. P., Wiviott S. D. et. al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events // N. Engl. J. Med. 2015. - Vol. 372. P. 1500-1509.
23. Giugliano R. P., Sabatine M. S. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? // J. Amer. Coll. Cardiol. 2015. Vol. 65, N 24. P. 2638- 2651.
24. Everett B. M., Smith R. J., Hiatt W. R. Reducing LDL with PCSK9 Inhibitors - The Clinical Benefit of Lipid Drugs // N. Engl. J. Med. 2015. Vol. 373, N 17. P. 1588-1591.
Review
For citations:
Bagriy A.E., Dyadyk A.I., Khomenko M.V., Tsiba I.N., Efremenko V.A., Shchukina E.V., Prikolota O.A. HYPOLIPIDEMIC MEDICATIONS: CURRENT USE AND FUTURE PERSPECTIVES. PART 1. NON-STATIN HYPOLIPIDEMIC MEDICATIONS. Ateroscleroz. 2016;12(1):61-68. (In Russ.)
Views:
859
Email this article 